Provided by Tiger Fintech (Singapore) Pte. Ltd.

Biomea Fusion, Inc.

2.54
-0.1200-4.51%
Post-market: 2.54-0.0001+0.00%19:42 EDT
Volume:655.54K
Turnover:1.70M
Market Cap:92.05M
PE:-0.63
High:2.80
Open:2.73
Low:2.48
Close:2.66
Loading ...

Biomea Fusion: Based on Most Recent Trial Results, Strategic Focus for Icovamenib Will Be in Metabolic Disorders

THOMSON REUTERS
·
13 Jan

3 US Penny Stocks With Market Caps Up To $2B

Simply Wall St.
·
09 Jan

Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX), Biomea Fusion (BMEA) and Solid Biosciences (SLDB)

TIPRANKS
·
09 Jan

Scotiabank Sticks to Its Buy Rating for Biomea Fusion (BMEA)

TIPRANKS
·
08 Jan

Biomea Fusion reports new preclinical data on icovamenib-semaglutide study

TIPRANKS
·
07 Jan

Biomea Fusion Reports New Preclinical Data on Icovamenib-Semaglutide Combination Study

THOMSON REUTERS
·
07 Jan

Biomea Fusion Inc - Icovamenib With Semaglutide Shows 11.5% Body Weight Reduction

THOMSON REUTERS
·
07 Jan

Here’s Why Biomea Fusion, Inc. (NASDAQ:BMEA) Is Among the Best Diabetes Stocks to Buy Under $10

Insider Monkey
·
06 Jan

Biomea Fusion Advances Diabetes Treatment with Positive Study Results

TIPRANKS
·
21 Dec 2024

Biomea Fusion Is Maintained at Buy by D. Boral Capital

Dow Jones
·
19 Dec 2024

Biomea Fusion Inc : Scotiabank Cuts Target Price to $30 From $41

THOMSON REUTERS
·
18 Dec 2024

Barclays Remains a Hold on Biomea Fusion (BMEA)

TIPRANKS
·
18 Dec 2024

Biomea Fusion price target lowered to $50 from $60 at Oppenheimer

TIPRANKS
·
18 Dec 2024

Why Is Diabetes-Drug Developer Biomea Fusion Stock Trading Lower On Tuesday?

Benzinga
·
17 Dec 2024

BRIEF-Biomea Fusion Announces Positive Topline Results From Ongoing Phase II COVALENT-111 Study

Reuters
·
17 Dec 2024

Biomea Fusion Announces Positive Topline Results From Ongoing Phase Ii Covalent-111 Study in Patients With Type 2 Diabetes

THOMSON REUTERS
·
17 Dec 2024